44results about How to "Specific targeting" patented technology

An internet target marketing system, method, and computer program for distributing online advertising to viewers based upon the viewers' interests is provided. Specific embodiments according to the present invention can use an n-way matching of user's concepts of interest, advertiser's concepts and a currently viewed document to target advertising to the view of the current document. Some embodiments can generate a contextually sensitive advertisement for each page viewed in a browser, thereby associating an advertisement with every page in a document. Specific embodiments can associate advertising with documents that are substantially free of embedded advertisements, for example. Alternative embodiments can include embedded advertising.

The movement of animals may be controlled by recording a sound which initiates movement in an animal and combining that movement initiating sound with additional sounds to produce music. A preferred embodiment uses the sound of one or more active dragonflies in combination with at least one of instrumental notes and sounds of nature to repel mosquitoes, flies and other closely related insects while attracting or entertaining humans.

The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3′, 5′-monophosphate analogs as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.

Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and / or diagnostic agents, for use in research and medical applications.

The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV / AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and / or decreases the number of monocytes and / or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.

The present invention discloses a novel anti-crop-epiphyte polypeptide and a preparation method thereof. A recombined anti-crop-epiphyte polypeptide is formed by linking gene which codes white candida pheromone and the gene which codes colicin. Compared with the prior anti-crop-epiphyte medicine, the novel anti-crop-epiphyte polypeptide of the present invention has the advantages that the novel anti-crop-epiphyte polypeptide directly forms ionic passage at epiphytic cell membrane to kill the epiphyte, so the killing efficiency is thousands times stronger than the prior anti-crop-epiphyte medicine; the epiphyte can hardly amend the geometrical damage at the cell membrane caused by the polypeptide by the mutation-expression form, so the polypeptide can not induce the epiphyte producing the traditional drug resistance; the polypeptide is a biological preparation and has target killing towards the epiphyte, so the novel anti-crop-epiphyte polypeptide does not have the toxic and side effects of the prior anti-crop-epiphyte medicine.

The present invention provides a uric acid-lowering molecule and its screening method and application. The amino acid sequence of the uric acid-lowering molecule is shown in SEQ ID NO.1; the present invention constructs a random mutation library by using phage display technology, and constructs a uric acid target molecule , using the principle of affinity adsorption to screen the library, optimize the construction, screening and identification methods and steps, and obtain the uric acid-lowering molecule, which is used to prepare a uric acid-lowering drug. The molecule has an excellent uric acid-lowering function, and the screening method is simple and efficient. It is worthy of popularization and application, and has broad application prospects and huge market value.

The invention discloses a complement receptor 2 variant, a fusion protein of the complement receptor 2 variant and a complement inhibitor and application of the fusion protein in preparing a medicament for treating autoimmune diseases. The complement receptor 2 variant is a molecular modified body obtained after computer modeling and amino acid replacement, has higher ligand binding and dissociation rate and better ligand binding force than a wild sequence of the complement receptor 2 variant. The biological distribution experiment proves that the fusion protein provided by the invention can rapidly and highly aggregate at an arthritis part after entering a rheumatoid arthritis mouse model, and has a remarkable anti-adhesion / anti-inflammation targeted inhibition effect. In the treatment ofMRL / lpr lupus erythematosus mice, the fusion protein can obviously improve the survival rate of the mice, and symptoms such as proteinuria, glomerular integral, interstitial inflammation, vasculitis,crescent / necrosis and the like of the mice in the treatment group are obviously improved.

The invention provides a gene, recombinant plasmid and polypeptide for an anti-tumor binary polypeptide. The gene of the recombinant anti-tumor binary polypeptide is obtained by connecting in an operable way the gene of a coding antibody simulator with a recombinant bacillus anthraci protein antigen gene. The recombinant plasmid of the invention is formed by inserting the gene of the coding antibody simulator by double-chain oligomeric nucleotide directed mutagenesis method into the recombinant bacillus anthraci protein antigen gene. The obtained recombinant plasmid is infected into engineering bacillus coli BL-21 to get engineering bacillus coli cell of anti-tumor binary polypeptide; the anti-tumor binary polypeptide can be obtained by expanding the bacillus coli, settling in centrifugalway the bacillus coli body, crushing in altrasonic way, settling and crushing bacillus coli body by hi-speed centrifuging and treating the upper clean solution. The anti-tumor binary polypeptide is of special targeting characteristic, higher efficiency in killing special physical tumor than prior anti-tumor medicine, and will not attack normal cells, and has much lower toxicity and poor-reactionthan prior anti-tumor medicine.